CoChat

GLP1 Receptor Agonist Liraglutide Is an Effective Therapeutic Option for Perioperative Glycemic Control in Type 2 Diabetes within Enhanced Recovery After Surgery (ERAS) Protocols

Kaneko, Shizuka, Ueda, Youhei, Tahara, Yumiko · 2018 · European Surgical Research

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

Background: Enhanced Recovery After Surgery (ERAS) protocols are multimodal perioperative care pathways designed to achieve early recovery after surgical procedures by maintaining preoperative organ function and reducing profound stress responses following surgery [Wilmore and Kehlet: BMJ 2001; 322(7284): 473–6]. Glucagon-like peptide-1 receptor agonists (GLP-1RAgs), such as liraglutide, have recently been widely used as antidiabetic agents in patients with type 2 diabetes (T2D) because they maintain blood glucose at an ideal level throughout the day, including during postprandial periods, thereby improving hypoglycemia and body weight more than insulin therapies. Additionally, the administration of liraglutide may exert cardiovascular, renal, and cerebral protective effects in T2D patients. The use of GLP-1RAgs for perioperative glycemic control is sometimes considered to be controversial. Methods: The efficacy and safety of liraglutide therapy during perioperative glycemic control in elective surgery patients within ERAS protocols were compared with those of insulin therapy. Ninety adult T2D patients scheduled to undergo elective surgery within ERAS protocols were randomized and analyzed. Forty-nine subjects were prescribed liraglutide and 41 insulin therapy. Procedures comprised orthopedic, thoracic, urological, otolaryngological, hepatic resection, and gynecological breast surgeries. Results: Liraglutide was shown to be a more effective option than insulin therapy because (1) glycemic levels were more stable; (2) the number of patients requiring additional insulin according to the insulin sliding scale was significantly smaller (Fisher’s exact test, p = 0.005); (3) the insulin dosage required on the day of surgery was significantly smaller (Fisher’s exact, p = 0.004); (4) the additional insulin volume required was significantly less for patients throughout the perioperative period (Fisher’s exact test, p = 0.001); and (5) while lean body mass remained the same, body fat measurements, particularly visceral fat, tended to decrease. Conclusions: Based on the results of the present study and a recent large-scale clinical study showing cardiovascular and renal protective effects in T2D patients, we consider the administration of liraglutide within ERAS protocols for T2D patients to represent a more comprehensive suite of patient protection measures as a perioperative non-insulin agent, particularly in patients with limited exercise ability and those at risk of hypoglycemia.

Overview

Integrity signals

Registry

Crossref · 10.1159/000494768

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Cited by

See all 32

Metadata

Authors
Kaneko, S., Ueda, Y., & Tahara, Y.
Affiliations
Takatsuki Red Cross Hospital (JP)
Venue
European Surgical Research
Publisher
S. Karger AG
Published
2018
Volume
59
Issue
5-6
Pages
349-360
ISSN
  • 0014-312X (ISSN-L)
  • 1421-9921
OpenAlex
W2905560533
Cited by
32
References
30
Citations by year
2026: 5 · 2025: 4 · 2024: 6 · 2023: 3 · 2022: 7 · 2021: 5 · 2020: 1 · 2019: 1
FWCI
1.40
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • European Surgical Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
Johnson and Johnson
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Health Sciences › Medicine › Surgery › Enhanced Recovery After Surgery
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
liraglutide, GLP-1 receptor agonists, type 2 diabetes, enhanced recovery after surgery, perioperative glycemic control, insulin therapy, elective surgery, visceral fat, body composition, sliding scale insulin, surgical stress response, postoperative recovery, drug safety and efficacy, orthopedic surgery, hepatectomy
MeSH terms
Liraglutide, Aged, Aged, 80 and over, Blood Glucose, Clinical Protocols, Diabetes Mellitus, Type 2, Female, Humans, Male, Middle Aged, Postoperative Complications, Perioperative Care, Recovery of Function, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP1 Receptor Agonist Liraglutide Is an Effective Therapeutic Option for Perioperative Glycemic Control in Type 2 Diabetes within Enhanced Recovery After Surgery (ERAS) Protocols. https://app.cochat.ai/papers/10.1159/000494768
The paper
Kaneko, S., Ueda, Y., & Tahara, Y. (2018). GLP1 Receptor Agonist Liraglutide Is an Effective Therapeutic Option for Perioperative Glycemic Control in Type 2 Diabetes within Enhanced Recovery After Surgery (ERAS) Protocols. European Surgical Research. https://doi.org/10.1159/000494768

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.